Dublin, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/bj...erapeutics ) has announced the addition of the "RNAi Therapeutics Market, 2015 - 2030" report to their offering. The RNAi Therapeutics Market, 2015-2030' report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of RNAi therapeutics. Overall, the RNAi therapeutics market has been one of the more actively evolving markets in the past few years. However, with no marketed products till date, the market is still in its infancy.
Discovered less than two decades ago, RNAi has made its presence felt in all spheres of the pharmaceutical industry. RNAi is a natural post-transcriptional process of gene silencing involving short strands of nucleic acids. It is a regulatory process that cells utilise to silence and/or inhibit gene expression through the destruction of specific mRNA molecules. One of the major advantages of RNAi is that it enables sequence specific knockdown of a target gene. Indications, such as age-related macular degeneration (AMD), hepatitis C and various forms of cancer,which are hard to address with the available therapies, are being considered as potential areas that can benefit from RNAi based therapeutics. After years of research tracing back to the 1990s, a number of novel RNAi therapeutics have finally reached a point of maturity. These promising therapeutic approaches are set to be made commercially available in the near future. Innovative research, encouraging clinical trial results and growing pipelines directed towards a variety of molecular targets across different therapeutic areas have emerged as essential growth drivers of the market. The promise has been backed by several venture capitalists and strategic investors. It is also important to highlight that partnerships amongst various stakeholders in this market have been common. Such collaborations have actively fuelled growth in the market by providing a common platform for both industry and academic research. Several start-ups / university spin-offs have been notable flagbearers and are expected to sustain the research momentum in the coming years. The commercial success, to a certain extent, is hinged upon uncovering effective delivery routes and developing sophisticated delivery carriers for the molecules. Despite this and other associated challenges, we expect the market to make a huge leap over the coming decade. Example Highlights - RNAi therapeutics have emerged as a new class of potent therapies capable of targeting diseases with undruggable targets. A number of disorders that are difficult to treat using traditional approaches can be addressed using this technology. - During the course of our research, we identified 180 products in various phases of development. Of these, 20% are in the clinical phase of development (with five molecules in Phase III trials). A significant proportion of the molecules (80%), currently in the preclinical/discovery stages,are likely to fuel the future growth. - The market is predominantly being led by emerging start-ups and small companies instead of big pharma companies. Alnylam Pharmaceuticals, Arbutus Biopharma (previously Tekmira), Benitec Biopharma and Quark Pharmaceuticals are some major players in this space. Other start-ups and university / industry spin offs that have come up in recent times include (in alphabetical order) Arrowhead Research, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics, Mirna Therapeutics, RXi Pharmaceuticals, Silence Therapeutics, Silenseed, Sirnaomics and Sylentis(full list available in Chapter 4). - A large number of players have already collaborated for licensing technology and therapeutic candidates. We have identified and reviewed over 80 such partnerships that have taken place in the last few years. One of the major reasons behind the extensive number of collaborations is that the original trigger and other related mechanisms are well protected through a number of patents. - In addition, enhanced technological platforms and unexplored opportunities have yielded an intense framework of investment activity, with a sizeable number of venture capitalists actively supporting the research. Since 2013, we have traced a total investment (equity + debt) of USD 2.2 billion. - Over the coming decade, we expect at least 11 RNAi therapies to be made commercially available. We believe the market is likely to be worth USD 18.6 billion by 2030; the overall opportunity could be much higher and depends on a number of factors such as favourable market environment, regulatory regimes and therapeutic performance of candidates in late stages of development. Key Topics Covered: 1 Preface 2 Executive Summary 3 Introduction 4 Market Overview 5 Technology Platforms And Delivery Systems 6 Regional Market 7 Market Forecast 8 Key Therapeutic Indications 9 RNAi And Diagnostics 10 Vc Funding In RNAi Therapeutics 11 Partnerships In RNAi Therapeutics 12 Service Providers In RNAi Therapeutics 13 SWOT Analysis 14 Conclusion Companies Mentioned - 4D Molecular Therapeutics - AbbVie - Abion - Abott Labs - Advirna - Aegerion Pharmaceuticals - Aligent Technologies - Allele Biotechnology - Altogen Labs - Alnylam Pharmaceuticals - Amarin - Ambion - Amgen - amsbio - AparnaBio - Arbutus Biopharma (previously Tekmira) - Archemix - Arcturus Therapeutics - Ariz Biopharma - Arrowhead Research Corporation - Artemis - Ascletis Pharmaceuticals - Asklepios - Astellas Pharma - AstraZeneca - Asuragen - Avidity NanoMedicines - Avocel - Bayer Heathcare - Benitec Biopharma - biOasis Technologies - Biocon - BioDefense Therapeutics - Biogazelle - Biogen - Biomics - Bioneer - BioSpring - Bristol-Myers Sqibb - Boehringer Ingelheim - Calando Pharmaceuticals - Caliber Biotherapeutics - Calimmune - Celgene - Cell Signaling Technology - Cellecta - Celsion Corporation - Cenix Biosciences - Cepheid - Circuit Therapeutics - CN Bio - CombiMatrix - Creative Animodel - Cubist - Dainppon Sumitomo Pharma - Dharmacon (GE unit) - DIAMIR - Dicerna Pharmaceuticals - Eisai - Eli Lilly - enGene - Ensysce Biosciences - Ethicor - Eurofins Genomics - Eurogentec - Exiqon - EyeGate Pharma - Eyetech - Genable - Genecare Research Institute - Genecon Biotech - GeneCopoeia - Genecust - GeneDesign - Genentech - GenePharma - General Research Laboratory - GenScript - Gensignia - Genzyme - Gilead Sciences - Gradalis - Groove Biopharma - GlaxoSmithKline - GuangshengZhongsheng - Guangzhou Xiangxue - Halo-bio - Horizon Discovery - Hugel - Interna Technologies - Intezyne - Ipsen - Isis Pharmaceuticals - Janssen Pharma - Kowa Pharmaceuticals - Kyowa Hakko Kirin - Life Technologies - Lonza - MD Anderson Cancer Center - Marina Biotech - Medtronic - Mello Biotech - Microlin Bio - Millennium Pharmaceuticals - miRagen Therapeutics - MiReven - MirImmune - Mirna Therapeutics - Mitsubishi Pharma Corporation - Monsanto - Merck & Co (US) - Nitto Denko Corporation - Novartis - Olix Pharmaceuticals - Omnia Biologics - Onco Therapy Science - OPKO - OriGene - PeptiMed - Pfizer - PhaseRx - Promega - Qiagen - QLT Phototherapeutics - Quark Pharmaceuticals - Regen BioPharma - Regulus Therapeutics - ReNeuron - Revivicor - Rhone Poulenc Rorer - Rosetta Genomics - RXi Therapeutics - Sankyo Co. - Sanofi-Aventis - Santaris Pharma/Roche - Sanwa Kagaku Kenkyusho - Schering - Seattle Genetics - Servier - Sevion Therapeutics - Shanghai Biotechnology Corporation - Shionogi & Co. - Sigma-Aldrich - Silence Therapeutics - Silenseed - Sirion Biotech - Sirnaomics - siRNAsense - siTools Biotech - Soluventis - Somagenics - Spectrum Pharmaceuticals - Sylentis - t2cure - Taisho Pharmaceuticals - Takeda Pharmaceutical Co. - The Medicines Company - TransDerm - Transgene Biotek - TransOMIC - UniQure - YuYu Pharma For more information visit http://www.researchandmarkets.com/research/bj...erapeutics
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Genomics
